Merck reported strong third-quarter performance with significant growth in key areas like KEYTRUDA, despite some challenges in the vaccines segment due to the pandemic. Management maintained a confident tone, highlighting strategic investments and an optimistic revenue outlook for 2021. The overall positive sales momentum and robust pipeline support a likely short-term positive impact on the stock.

[1]